Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain
about
Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2018
@uk
name
Cost-Effectiveness Analysis of ...... in High-Risk Patients in Spain
@en
Cost-Effectiveness Analysis of ...... in High-Risk Patients in Spain
@nl
type
label
Cost-Effectiveness Analysis of ...... in High-Risk Patients in Spain
@en
Cost-Effectiveness Analysis of ...... in High-Risk Patients in Spain
@nl
prefLabel
Cost-Effectiveness Analysis of ...... in High-Risk Patients in Spain
@en
Cost-Effectiveness Analysis of ...... in High-Risk Patients in Spain
@nl
P2093
P2860
P1433
P1476
Cost-Effectiveness Analysis of ...... in High-Risk Patients in Spain
@en
P2093
Belén Aragón
Javier Cobo
Miguel Salavert
Santiago Grau
Stefano Maratia
Susana Aceituno
Yiling Jiang
P2860
P2888
P304
P356
10.1007/S12325-018-0813-Y
P407
P577
2018-10-16T00:00:00Z